董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gili Hart | 女 | Director | 45 | 未披露 | 未持股 | 2020-04-01 |
| Roger Pomerantz | 男 | Chairman of the Board and Director | 63 | 未披露 | 未持股 | 2020-04-01 |
| Joseph Zarzewsky | 男 | Director | 59 | 未披露 | 未持股 | 2020-04-01 |
| Elan Penn | 男 | Director | 68 | 未披露 | 未持股 | 2020-04-01 |
| Abraham Havron | 男 | Director | 72 | 未披露 | 未持股 | 2020-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yehiel Tal | 男 | Chief Executive Officer | 67 | 37.50万美元 | 未持股 | 2020-04-01 |
| Oded Shoseyov | 男 | Founder, Chief Scientist | 63 | 33.50万美元 | 未持股 | 2020-04-01 |
| Eran Rotem | 男 | Deputy CEO and Chief Financial Officer | 52 | 29.40万美元 | 未持股 | 2020-04-01 |
| Ilana Belzer | 男 | Chief Operating Officer | 60 | 未披露 | 未持股 | 2020-04-01 |
| Nadav Orr | 男 | Vice President, Research and Development | 62 | 21.60万美元 | 未持股 | 2020-04-01 |
| Philippe Bensimon | 男 | Vice President, Regulatory Affairs and Quality Assurance | 54 | 24.40万美元 | 未持股 | 2020-04-01 |
董事简历
中英对照 | 中文 | 英文- Gili Hart
-
Gili Hart自2014年以来一直担任公司董事。Hart博士此前曾在Opko Biologics F.K.A.Prolor Biotech担任多个职位，并于2008年至2018年转到Mitoconix Bio Ltd.（一家生物制药公司，开发疾病修改疗法，通过改善线粒体健康来满足未满足的医疗需求）之前领导那里的临床前，临床和药理活动，她目前担任首席执行官。Hart博士从2005年到2007年是耶鲁大学免疫学系的研究员，也是以色列魏茨曼科学研究所（Weizmann Institute of Science）免疫学系的研究员。Hart博士目前担任Collplant Holdings Ltd.（CLGN）的董事会成员，她自2017年以来一直担任该职位。Hart博士以优异成绩从魏茨曼免疫学科学研究所免疫学部门获得博士学位，并以优异成绩从以色列Technion研究所获得生物技术工程硕士学位。Hart博士发表了许多论文和专利，在每种情况下都专注于自身免疫性疾病和免疫系统激活。
Gili Hart has been a Director of the Company since 2014. Dr. Hart previously held various positions at OPKO Biologics f.k.a. PROLOR Biotech and led the pre-clinical, clinical and pharmacological activities there from 2008 until her move in 2018 to Mitoconix Bio Ltd., a biopharmaceutical company developing disease modifying therapies addressing unmet medical needs by improving mitochondrial health, where she currently serves as Chief Executive Officer. Dr. Hart was a research fellow in the Immunology Department of Yale University from 2005 to 2007 and a research fellow at the Immunology Department of the Weizmann Institute of Science in Israel. Dr. Hart currently serves as a member of the board of directors of Collplant Holdings Ltd. (CLGN), which position she has held since 2017. Dr. Hart received her Ph.D. with distinction from the Immunology Department of the Weizmann Institute of Science in Immunology, and a M.S. degree in Biotechnology Engineering, summa cum laude, from the Technion Institute in Israel. Dr. Hart has published numerous papers and patents, in each case focusing on autoimmunity disease and immune system activation. - Gili Hart自2014年以来一直担任公司董事。Hart博士此前曾在Opko Biologics F.K.A.Prolor Biotech担任多个职位，并于2008年至2018年转到Mitoconix Bio Ltd.（一家生物制药公司，开发疾病修改疗法，通过改善线粒体健康来满足未满足的医疗需求）之前领导那里的临床前，临床和药理活动，她目前担任首席执行官。Hart博士从2005年到2007年是耶鲁大学免疫学系的研究员，也是以色列魏茨曼科学研究所（Weizmann Institute of Science）免疫学系的研究员。Hart博士目前担任Collplant Holdings Ltd.（CLGN）的董事会成员，她自2017年以来一直担任该职位。Hart博士以优异成绩从魏茨曼免疫学科学研究所免疫学部门获得博士学位，并以优异成绩从以色列Technion研究所获得生物技术工程硕士学位。Hart博士发表了许多论文和专利，在每种情况下都专注于自身免疫性疾病和免疫系统激活。
- Gili Hart has been a Director of the Company since 2014. Dr. Hart previously held various positions at OPKO Biologics f.k.a. PROLOR Biotech and led the pre-clinical, clinical and pharmacological activities there from 2008 until her move in 2018 to Mitoconix Bio Ltd., a biopharmaceutical company developing disease modifying therapies addressing unmet medical needs by improving mitochondrial health, where she currently serves as Chief Executive Officer. Dr. Hart was a research fellow in the Immunology Department of Yale University from 2005 to 2007 and a research fellow at the Immunology Department of the Weizmann Institute of Science in Israel. Dr. Hart currently serves as a member of the board of directors of Collplant Holdings Ltd. (CLGN), which position she has held since 2017. Dr. Hart received her Ph.D. with distinction from the Immunology Department of the Weizmann Institute of Science in Immunology, and a M.S. degree in Biotechnology Engineering, summa cum laude, from the Technion Institute in Israel. Dr. Hart has published numerous papers and patents, in each case focusing on autoimmunity disease and immune system activation.
- Roger Pomerantz
-
Roger Pomerantz自2020年2月以来一直担任我们的董事会主席。Pomerantz博士目前是Contrafect的总裁、首席执行官和董事会主席，以及Intec Pharma和Verimmune的董事会成员。Pomerantz博士于2019年担任Seres Therapeutics的董事会主席，在那里他于2014年6月至2019年1月担任董事长兼首席执行官。从2011年到2013年，他曾担任Merck Research Laboratories公司的许可和收购、高级副总裁全球主管，在那里他曾监管默克制药公司公司的所有许可和收购。此前，他曾担任默克公司（Merck）传染病高级副总裁和全球特许经营主管。在加入默克公司之前，Pomerantz博士是强生公司制药公司传染病全球主管。他于2005年加入强生公司，担任Tibotec Pharmaceuticals，Inc.的总裁。Pomerantz博士在约翰霍普金斯大学（Johns Hopkins University）获得生物化学学士学位，并在约翰霍普金斯医学院（Johns Hopkins School of Medicine）获得医学博士学位。他在Massachusetts General Hospital，Harvard Medical School接受研究生培训，M.I.T.Dr.Pomerantz获得内科和传染病委员会认证。他曾担任医学、生物化学和分子药理学教授、传染病首席，以及Thomas Jefferson University and Medical School的人类病毒学和生物防御研究所的创始董事兼主席。他在重要疾病，包括HIV、HCV、CMV、C.diff和结核病，开发了12种全球批准的小分子和大分子药物。
Roger Pomerantz has served as our Chairman of the board of directors since February 2020. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect, and a board member of Intec Pharma and VerImmune. Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics in 2019 where he served as Chairman and CEO from June 2014 until January 2019. From 2011 to 2013 he was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed twelve small and large molecular drugs approved world-wide in important diseases, including HIV, HCV, CMV, C. Diff, and tuberculosis. - Roger Pomerantz自2020年2月以来一直担任我们的董事会主席。Pomerantz博士目前是Contrafect的总裁、首席执行官和董事会主席，以及Intec Pharma和Verimmune的董事会成员。Pomerantz博士于2019年担任Seres Therapeutics的董事会主席，在那里他于2014年6月至2019年1月担任董事长兼首席执行官。从2011年到2013年，他曾担任Merck Research Laboratories公司的许可和收购、高级副总裁全球主管，在那里他曾监管默克制药公司公司的所有许可和收购。此前，他曾担任默克公司（Merck）传染病高级副总裁和全球特许经营主管。在加入默克公司之前，Pomerantz博士是强生公司制药公司传染病全球主管。他于2005年加入强生公司，担任Tibotec Pharmaceuticals，Inc.的总裁。Pomerantz博士在约翰霍普金斯大学（Johns Hopkins University）获得生物化学学士学位，并在约翰霍普金斯医学院（Johns Hopkins School of Medicine）获得医学博士学位。他在Massachusetts General Hospital，Harvard Medical School接受研究生培训，M.I.T.Dr.Pomerantz获得内科和传染病委员会认证。他曾担任医学、生物化学和分子药理学教授、传染病首席，以及Thomas Jefferson University and Medical School的人类病毒学和生物防御研究所的创始董事兼主席。他在重要疾病，包括HIV、HCV、CMV、C.diff和结核病，开发了12种全球批准的小分子和大分子药物。
- Roger Pomerantz has served as our Chairman of the board of directors since February 2020. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect, and a board member of Intec Pharma and VerImmune. Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics in 2019 where he served as Chairman and CEO from June 2014 until January 2019. From 2011 to 2013 he was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed twelve small and large molecular drugs approved world-wide in important diseases, including HIV, HCV, CMV, C. Diff, and tuberculosis.
- Joseph Zarzewsky
-
Joseph Zarzewsky自2010年6月以来一直担任Mitrelli Group（简称Mitrelli）的业务开发Vice President。Zarzewsky先生自2011年6月起担任“；Smad”；的董事长，该公司是Mitrelli与中国哈尔滨政府的合资企业。Zarzewsky先生自2012年以来还担任Harbin Israel Fund的投资委员会主席，并担任Wize Pharma，Inc.的董事会成员。OTCQB:Wizp自2017年11月起。他也曾担任Clal Insurance Enterprises Holdings Ltd.的营销Vice President。TASE:CLIS并担任以色列邮政管理局的营销Vice President。此外，Zarzewsky先生自2007年起担任Excellence Underwriter House Ltd.的董事。2008年他被任命为中国哈尔滨政府荣誉经济顾问。此外，2012年6月他被授予中国哈尔滨荣誉公民称号。Zarzewsky先生拥有特拉维夫大学（University of Tel Aviv）与加州大学伯克利分校（University of California，Berkeley）合作的商法硕士学位。
Joseph Zarzewsky has served as the Vice President of Business Development at the Mitrelli Group, or Mitrelli, since June 2010. Mr. Zarzewsky has served as the Chairman of “SMAD”, a joint venture between Mitrelli and the Harbin Government, China, since June 2011. Mr. Zarzewsky has also served as the Chairman of the Investment Committee of the Harbin Israel Fund since 2012 and as a member of the board of directors of Wize Pharma, Inc. OTCQB: WIZP since November 2017. He has also previously served as the Vice President of marketing at Clal Insurance Enterprises Holdings Ltd. TASE: CLIS and as the Vice President of Marketing for the Israel Postal Authority. In addition, Mr. Zarzewsky has served as a director of Excellence Underwriter House Ltd. since 2007. In 2008 he was appointed as the Honorary Economic Advisor of the Harbin Government, China. In addition, in June 2012 he was honored as an Honorary Citizen of Harbin, China. Mr. Zarzewsky holds an MA in Commercial Law from the University of Tel Aviv in collaboration with the University of California, Berkeley. - Joseph Zarzewsky自2010年6月以来一直担任Mitrelli Group（简称Mitrelli）的业务开发Vice President。Zarzewsky先生自2011年6月起担任“；Smad”；的董事长，该公司是Mitrelli与中国哈尔滨政府的合资企业。Zarzewsky先生自2012年以来还担任Harbin Israel Fund的投资委员会主席，并担任Wize Pharma，Inc.的董事会成员。OTCQB:Wizp自2017年11月起。他也曾担任Clal Insurance Enterprises Holdings Ltd.的营销Vice President。TASE:CLIS并担任以色列邮政管理局的营销Vice President。此外，Zarzewsky先生自2007年起担任Excellence Underwriter House Ltd.的董事。2008年他被任命为中国哈尔滨政府荣誉经济顾问。此外，2012年6月他被授予中国哈尔滨荣誉公民称号。Zarzewsky先生拥有特拉维夫大学（University of Tel Aviv）与加州大学伯克利分校（University of California，Berkeley）合作的商法硕士学位。
- Joseph Zarzewsky has served as the Vice President of Business Development at the Mitrelli Group, or Mitrelli, since June 2010. Mr. Zarzewsky has served as the Chairman of “SMAD”, a joint venture between Mitrelli and the Harbin Government, China, since June 2011. Mr. Zarzewsky has also served as the Chairman of the Investment Committee of the Harbin Israel Fund since 2012 and as a member of the board of directors of Wize Pharma, Inc. OTCQB: WIZP since November 2017. He has also previously served as the Vice President of marketing at Clal Insurance Enterprises Holdings Ltd. TASE: CLIS and as the Vice President of Marketing for the Israel Postal Authority. In addition, Mr. Zarzewsky has served as a director of Excellence Underwriter House Ltd. since 2007. In 2008 he was appointed as the Honorary Economic Advisor of the Harbin Government, China. In addition, in June 2012 he was honored as an Honorary Citizen of Harbin, China. Mr. Zarzewsky holds an MA in Commercial Law from the University of Tel Aviv in collaboration with the University of California, Berkeley.
- Elan Penn
-
Elan Penn自2018年1月以来一直在CollPlant Biotechnologies Ltd.的董事会任职。自2001年以来，Penn博士一直担任Penn Publishing Ltd.的首席执行官兼董事长，该公司是一家位于以色列特拉维夫的私营公司。从2000年到2001年，Penn博士担任A.I. Research and Development Ltd.的财务和行政副总裁。Penn博士在1998年至2000年期间担任Sivan Computer Training Company Ltd.的首席执行官。从1992年到2000年，Penn博士担任Mashov Computers Ltd.的财务和行政副总裁。从1987年到1991年，再次从1992年到1997年，Penn博士担任Magic Software Enterprises Ltd.的财务和行政副总裁。纳斯达克股票代码：MGIC和，2005年至2014年担任Magic Software的外部董事。Penn博士曾担任Telkoor Power Supplies Ltd.的董事。TASE：TLCR和Nexgen Biofuels Ltd.（前身为医疗保健技术有限公司）（场外交易代码：NXGN）。Penn博士拥有学士学位。耶路撒冷希伯来大学经济学学位和博士学位。伦敦大学管理科学博士。
Elan Penn has served on CollPlant Biotechnologies Ltd.'s board of directors since January 2018. Dr. Penn has served as chief executive officer and chairman of Penn Publishing Ltd., a private company based in Tel Aviv, Israel, since 2001. From 2000 to 2001 Dr. Penn served as vice president of finance and administration of A.I. Research and Development Ltd. Dr. Penn served as chief executive officer of Sivan Computer Training Company Ltd. during the years 1998 through 2000. From 1992 to 2000 Dr. Penn served as vice president of finance and administration of Mashov Computers Ltd. From 1987 to 1991 and again from 1992 to 1997 Dr. Penn served as vice president of finance and administration of Magic Software Enterprises Ltd. NASDAQ: MGIC and, from 2005 to 2014 served as an external director of Magic Software. Dr. Penn previously served as a director of Telkoor Power Supplies Ltd. TASE: TLCR and Nexgen Biofuels Ltd. (formerly Healthcare Technologies Ltd) (OTC: NXGN). Dr. Penn holds a B.A. degree in Economics from the Hebrew University of Jerusalem and a Ph.D. in Management Science from the University of London. - Elan Penn自2018年1月以来一直在CollPlant Biotechnologies Ltd.的董事会任职。自2001年以来，Penn博士一直担任Penn Publishing Ltd.的首席执行官兼董事长，该公司是一家位于以色列特拉维夫的私营公司。从2000年到2001年，Penn博士担任A.I. Research and Development Ltd.的财务和行政副总裁。Penn博士在1998年至2000年期间担任Sivan Computer Training Company Ltd.的首席执行官。从1992年到2000年，Penn博士担任Mashov Computers Ltd.的财务和行政副总裁。从1987年到1991年，再次从1992年到1997年，Penn博士担任Magic Software Enterprises Ltd.的财务和行政副总裁。纳斯达克股票代码：MGIC和，2005年至2014年担任Magic Software的外部董事。Penn博士曾担任Telkoor Power Supplies Ltd.的董事。TASE：TLCR和Nexgen Biofuels Ltd.（前身为医疗保健技术有限公司）（场外交易代码：NXGN）。Penn博士拥有学士学位。耶路撒冷希伯来大学经济学学位和博士学位。伦敦大学管理科学博士。
- Elan Penn has served on CollPlant Biotechnologies Ltd.'s board of directors since January 2018. Dr. Penn has served as chief executive officer and chairman of Penn Publishing Ltd., a private company based in Tel Aviv, Israel, since 2001. From 2000 to 2001 Dr. Penn served as vice president of finance and administration of A.I. Research and Development Ltd. Dr. Penn served as chief executive officer of Sivan Computer Training Company Ltd. during the years 1998 through 2000. From 1992 to 2000 Dr. Penn served as vice president of finance and administration of Mashov Computers Ltd. From 1987 to 1991 and again from 1992 to 1997 Dr. Penn served as vice president of finance and administration of Magic Software Enterprises Ltd. NASDAQ: MGIC and, from 2005 to 2014 served as an external director of Magic Software. Dr. Penn previously served as a director of Telkoor Power Supplies Ltd. TASE: TLCR and Nexgen Biofuels Ltd. (formerly Healthcare Technologies Ltd) (OTC: NXGN). Dr. Penn holds a B.A. degree in Economics from the Hebrew University of Jerusalem and a Ph.D. in Management Science from the University of London.
- Abraham Havron
-
Abraham Havron，他曾担任我们的董事（2014年6月以来）。2005年以来，他曾一直担任PROLOR Biotech公司（2013年公司与OPKO Health公司合并）的首席执行官兼董事。他也是Kamada公司的外部董事，也任职于其审计委员会和薪酬委员会。他拥有34年的生物技术产业经验，也曾担任Interpharm Laboratories公司（Merck Serono公司的子公司）的创始团队成员，以及研发董事（1980年至1987年）。他曾担任BioTechnology General公司（位于以色列雷霍沃特，目前是Ferring Pharmaceuticals公司的一个部门）的生产和过程开发副总裁（1987年至1999年），以及Clal Biotechnology Industries公司的副总裁兼首席技术官（1999年至2003年）。他持有the Weizmann Institute of Science的生物有机化学博士学位，也曾担任哈佛医学院放射学研究员。
Abraham Havron has been a Director of the Company since 2014. Dr. Havron served as the Chief Executive Officer of PROLOR Biotech, Inc. from 2005 through 2013. Dr. Havron is a 35-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development of Interpharm Laboratories then, a subsidiary of Serono, later acquired by Merck from 1980 to 1987 and headed the development of the multiple sclerosis drug REBIF, with current sales of more than $1.5 billion annually. Dr. Havron served as Vice-President Manufacturing and Process-Development of BioTechnology General Ltd., from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. Dr. Havron’s managerial responsibilities included the co-development of several therapeutic proteins and other bio-pharmaceuticals currently in the market, including recombinant human growth hormone (BioTropin), recombinant Hepatitis B Vaccine (Bio-Hep-B), recombinant Beta Interferon (REBIF), recombinant human insulin and hyaluronic acid for ophthalmic and orthopedic applications. Dr. Havron earned his Ph.D. in Bio-Organic Chemistry from the Weizmann Institute of Science, and served as a Research Fellow in the Harvard Medical School, Department of Radiology. Dr. Havron served as a director of Kamada Ltd. (KMDA) from 2010 to 2018. Dr. Havron also currently serves on the board of directors of Collplant Holdings Ltd. (CLGN), which position he has held since 2016 and PamBio, a private biotech company. - Abraham Havron，他曾担任我们的董事（2014年6月以来）。2005年以来，他曾一直担任PROLOR Biotech公司（2013年公司与OPKO Health公司合并）的首席执行官兼董事。他也是Kamada公司的外部董事，也任职于其审计委员会和薪酬委员会。他拥有34年的生物技术产业经验，也曾担任Interpharm Laboratories公司（Merck Serono公司的子公司）的创始团队成员，以及研发董事（1980年至1987年）。他曾担任BioTechnology General公司（位于以色列雷霍沃特，目前是Ferring Pharmaceuticals公司的一个部门）的生产和过程开发副总裁（1987年至1999年），以及Clal Biotechnology Industries公司的副总裁兼首席技术官（1999年至2003年）。他持有the Weizmann Institute of Science的生物有机化学博士学位，也曾担任哈佛医学院放射学研究员。
- Abraham Havron has been a Director of the Company since 2014. Dr. Havron served as the Chief Executive Officer of PROLOR Biotech, Inc. from 2005 through 2013. Dr. Havron is a 35-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development of Interpharm Laboratories then, a subsidiary of Serono, later acquired by Merck from 1980 to 1987 and headed the development of the multiple sclerosis drug REBIF, with current sales of more than $1.5 billion annually. Dr. Havron served as Vice-President Manufacturing and Process-Development of BioTechnology General Ltd., from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. Dr. Havron’s managerial responsibilities included the co-development of several therapeutic proteins and other bio-pharmaceuticals currently in the market, including recombinant human growth hormone (BioTropin), recombinant Hepatitis B Vaccine (Bio-Hep-B), recombinant Beta Interferon (REBIF), recombinant human insulin and hyaluronic acid for ophthalmic and orthopedic applications. Dr. Havron earned his Ph.D. in Bio-Organic Chemistry from the Weizmann Institute of Science, and served as a Research Fellow in the Harvard Medical School, Department of Radiology. Dr. Havron served as a director of Kamada Ltd. (KMDA) from 2010 to 2018. Dr. Havron also currently serves on the board of directors of Collplant Holdings Ltd. (CLGN), which position he has held since 2016 and PamBio, a private biotech company.
高管简历
中英对照 | 中文 | 英文- Yehiel Tal
Yehiel Talhas，2010年1月以来，他一直担任我们的首席执行官。他拥有20年以上的以色列和美国高科技和生物技术产业管理经验。加入我们之前，他曾担任Regentis Biomaterials Ltd的首席执行官兼联席创始人。此前，他曾担任ProChon BioTech Ltd的商业开发副总裁。他也曾担任OrthoScan Technologies Ltd的营销和商业开发副总裁，以及Kulicke and Soffa Industries, Inc的商业开发主管和商业单位经理。他持有the Technion, Israel Institute of Technology的机械工程硕士学位。
Yehiel Tal has served as our chief executive officer since January 2010. Mr. Tal possesses over 30 years of management experience in the Israeli and American high-tech and biotechnology industries. Prior to joining us, Mr. Tal was the chief executive officer and co-founder of Regentis Biomaterials Ltd. Prior to that Mr. Tal served as vice-president of business development at ProChon BioTech Ltd. He has also served as vice president of marketing and business development at OrthoScan Technologies Ltd. and director of business development and business unit manager at Kulicke and Soffa Industries, Inc. Mr. Tal holds a Bachelor’s and a Master’s degree in mechanical engineering from the Technion, Israel Institute of Technology.- Yehiel Talhas，2010年1月以来，他一直担任我们的首席执行官。他拥有20年以上的以色列和美国高科技和生物技术产业管理经验。加入我们之前，他曾担任Regentis Biomaterials Ltd的首席执行官兼联席创始人。此前，他曾担任ProChon BioTech Ltd的商业开发副总裁。他也曾担任OrthoScan Technologies Ltd的营销和商业开发副总裁，以及Kulicke and Soffa Industries, Inc的商业开发主管和商业单位经理。他持有the Technion, Israel Institute of Technology的机械工程硕士学位。
- Yehiel Tal has served as our chief executive officer since January 2010. Mr. Tal possesses over 30 years of management experience in the Israeli and American high-tech and biotechnology industries. Prior to joining us, Mr. Tal was the chief executive officer and co-founder of Regentis Biomaterials Ltd. Prior to that Mr. Tal served as vice-president of business development at ProChon BioTech Ltd. He has also served as vice president of marketing and business development at OrthoScan Technologies Ltd. and director of business development and business unit manager at Kulicke and Soffa Industries, Inc. Mr. Tal holds a Bachelor’s and a Master’s degree in mechanical engineering from the Technion, Israel Institute of Technology.
- Oded Shoseyov
Oded Shoseyov，于2004年创立我们的公司，也曾担任我们的首席科学官（2008年8月以来），也曾担任我们的董事会成员（2010年5月至2016年10月）。他是the Hebrew University of Jerusalem的教职工。他拥有植物转换系统和蛋白质工程的丰富经验。他曾撰写和共同撰写160多个科学出版物，也是45项专利的发明者和共同发明者。他持有The Hebrew University（位于以色列耶路撒冷）的哲学博士学位。他持有2002年波兰的杰出科学家奖、1999年和2010年创新和应用研究凯奖、2012年创业和创新以色列总理嘉奖。他是9家公司的科学创始人，其中包括Fulcrum Materials Ltd.（纳米生物技术公司，制造复合材料行业SP1-Carbon纳米管涂层织物）、CBD-Technologies/FuturaGene（林业农业生物技术公司，开发和商业化纸浆和纸张和生物燃料产业的转基因树木）、Melodea Ltd.（纳米生物技术公司，研发和制造纳米固体结晶纤维素，从构造泡沫污泥、燃烧和喷气发动机以及炸药的燃料）、Valentis Nanotech Ltd（纳米技术公司，研发和制造食品包装和农业的纳米生物透明薄膜）。
Oded Shoseyov founded our subsidiary CollPlant Ltd. in 2004 and currently serves as our Chief Scientist since March 2019. Prof. Shoseyov served as our Chief Scientific Officer from August 2008 until March 2019 and a member of our board of directors from May 2010 until October 2016. Prof. Shoseyov is a faculty member of the Hebrew University of Jerusalem. He has extensive experience with plant transformation systems and protein engineering. Prof. Shoseyov has authored or co-authored over 160 scientific publications and is the inventor or co-inventor of 45 patents. Prof. Shoseyov holds a Ph.D. from The Hebrew University of Jerusalem, Israel. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002 the 1999 and 2010 Kay Awards for Innovative and Applied Research, and The 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. He is the scientific founder of nine companies, including: SP-Nano Ltd., a nano-biotech company which manufactures SP1-Carbon Nano Tube coated fabrics for the composite industry; CBD-Technologies/FuturaGene, a forestry agro-biotech company that develops and commercializes transgenic trees for the pulp and paper and the bio-fuel industry; Melodea Ltd., a nano-biotech company that develops and manufactures Nano Crystaline Cellulose from sludge for structural foam additives for the paint, printing and packaging industries; and Valentis Nanotech Ltd., a nanotechnology company that develops and manufactures nano-bio-based transparent films for food packaging and agriculture.- Oded Shoseyov，于2004年创立我们的公司，也曾担任我们的首席科学官（2008年8月以来），也曾担任我们的董事会成员（2010年5月至2016年10月）。他是the Hebrew University of Jerusalem的教职工。他拥有植物转换系统和蛋白质工程的丰富经验。他曾撰写和共同撰写160多个科学出版物，也是45项专利的发明者和共同发明者。他持有The Hebrew University（位于以色列耶路撒冷）的哲学博士学位。他持有2002年波兰的杰出科学家奖、1999年和2010年创新和应用研究凯奖、2012年创业和创新以色列总理嘉奖。他是9家公司的科学创始人，其中包括Fulcrum Materials Ltd.（纳米生物技术公司，制造复合材料行业SP1-Carbon纳米管涂层织物）、CBD-Technologies/FuturaGene（林业农业生物技术公司，开发和商业化纸浆和纸张和生物燃料产业的转基因树木）、Melodea Ltd.（纳米生物技术公司，研发和制造纳米固体结晶纤维素，从构造泡沫污泥、燃烧和喷气发动机以及炸药的燃料）、Valentis Nanotech Ltd（纳米技术公司，研发和制造食品包装和农业的纳米生物透明薄膜）。
- Oded Shoseyov founded our subsidiary CollPlant Ltd. in 2004 and currently serves as our Chief Scientist since March 2019. Prof. Shoseyov served as our Chief Scientific Officer from August 2008 until March 2019 and a member of our board of directors from May 2010 until October 2016. Prof. Shoseyov is a faculty member of the Hebrew University of Jerusalem. He has extensive experience with plant transformation systems and protein engineering. Prof. Shoseyov has authored or co-authored over 160 scientific publications and is the inventor or co-inventor of 45 patents. Prof. Shoseyov holds a Ph.D. from The Hebrew University of Jerusalem, Israel. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002 the 1999 and 2010 Kay Awards for Innovative and Applied Research, and The 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. He is the scientific founder of nine companies, including: SP-Nano Ltd., a nano-biotech company which manufactures SP1-Carbon Nano Tube coated fabrics for the composite industry; CBD-Technologies/FuturaGene, a forestry agro-biotech company that develops and commercializes transgenic trees for the pulp and paper and the bio-fuel industry; Melodea Ltd., a nano-biotech company that develops and manufactures Nano Crystaline Cellulose from sludge for structural foam additives for the paint, printing and packaging industries; and Valentis Nanotech Ltd., a nanotechnology company that develops and manufactures nano-bio-based transparent films for food packaging and agriculture.
- Eran Rotem
Eran Rotem，2012年1月以来，他一直担任我们的首席财务官。他拥有20年的广泛的财务和运营经验，主要任职生物技术和工业企业。加入我们之前，他曾担任Tefron Ltd（工业全球公司，在特拉维夫股票交易所交易，TASE：TFRN）、the OTCBB （OTC：TFRFF）（位于美国）的首席财务官。任职Tefron公司之前，他曾担任Healthcare Technologies, Ltd. （NASDAQ：HCTL）、Gamida Ltd（公司专门从事开发、制造、营销临床诊断检测盒，以及生物技术产业和高科技产业的医疗设备和服务）的首席财务官。加入Healthcare Technologies, Ltd.之前，他曾担任Ernst & Young公司的高级经理。他持有the Tel Aviv College of Management的会计和工商管理学士学位，也是注册会计师。
Eran Rotem has served as our chief financial officer since January 2012 and, since November 2017 also as our deputy CEO. Mr. Rotem possesses 25 years of broad financial and operational experience, primarily with biotechnology and industrial companies. Prior to joining us, Mr. Rotem served as the chief financial officer of Tefron Ltd., an industrial global company traded on both the Tel Aviv Stock Exchange TASE:TFRN and on the OTCBB OTC:TFRFF in the United States. Before Tefron, Mr. Rotem served as chief financial officer of Healthcare Technologies, Ltd. (NASDAQ:HCTL) and Gamida Ltd., a group of companies that specialize in the development, manufacturing, and marketing of clinical diagnostic test kits, as well as medical equipment and services to the biotechnology and high-tech industries. Prior to joining Healthcare Technologies, Ltd., Mr. Rotem served as a senior manager at Ernst & Young. Mr. Rotem holds a Bachelor’s degree in Accounting and Business Administration from the Tel Aviv College of Management and is a Certified Public Accountant in Israel.- Eran Rotem，2012年1月以来，他一直担任我们的首席财务官。他拥有20年的广泛的财务和运营经验，主要任职生物技术和工业企业。加入我们之前，他曾担任Tefron Ltd（工业全球公司，在特拉维夫股票交易所交易，TASE：TFRN）、the OTCBB （OTC：TFRFF）（位于美国）的首席财务官。任职Tefron公司之前，他曾担任Healthcare Technologies, Ltd. （NASDAQ：HCTL）、Gamida Ltd（公司专门从事开发、制造、营销临床诊断检测盒，以及生物技术产业和高科技产业的医疗设备和服务）的首席财务官。加入Healthcare Technologies, Ltd.之前，他曾担任Ernst & Young公司的高级经理。他持有the Tel Aviv College of Management的会计和工商管理学士学位，也是注册会计师。
- Eran Rotem has served as our chief financial officer since January 2012 and, since November 2017 also as our deputy CEO. Mr. Rotem possesses 25 years of broad financial and operational experience, primarily with biotechnology and industrial companies. Prior to joining us, Mr. Rotem served as the chief financial officer of Tefron Ltd., an industrial global company traded on both the Tel Aviv Stock Exchange TASE:TFRN and on the OTCBB OTC:TFRFF in the United States. Before Tefron, Mr. Rotem served as chief financial officer of Healthcare Technologies, Ltd. (NASDAQ:HCTL) and Gamida Ltd., a group of companies that specialize in the development, manufacturing, and marketing of clinical diagnostic test kits, as well as medical equipment and services to the biotechnology and high-tech industries. Prior to joining Healthcare Technologies, Ltd., Mr. Rotem served as a senior manager at Ernst & Young. Mr. Rotem holds a Bachelor’s degree in Accounting and Business Administration from the Tel Aviv College of Management and is a Certified Public Accountant in Israel.
- Ilana Belzer
Ilana Belzer，2015年10月以来，他一直担任我们的首席运营官。加入我们之前，他曾担任BioHarvest公司（创新生物科技公司）的首席运营官（2012年10月至2015年9月），此前曾担任Procognia Ltd的研发运营副总裁。此前，他曾担任Omrix Biopharmaceuticals Inc.（目前从属于the Johnson & Johnson家族公司）、InterPharm Labratories Ltd（Merck-Serono的子公司）的执行职务。他持有Tel Aviv University（位于以色列）的微生物和细胞生物学硕士学位、学士学位和博士学位。
Ilana Belzer has served as our chief operating officer since October 2015. Prior to joining us, Dr. Belzer served as the chief operating officer of BioHarvest, an innovative biotechnology company, from October 2012 to September 2015 and prior to that as vice president of research and development and operations at Procognia Ltd. Prior to that, Dr. Belzer held executive positions in Omrix Biopharmaceuticals Inc., now part of the Johnson & Johnson family of companies, and InterPharm Laboratories Ltd., now a subsidiary of Merck-Serono. Dr. Belzer holds an M.Sc., a B.Sc. and a Ph.D. in Microbiology and Cell Biology from Tel Aviv University, Israel.- Ilana Belzer，2015年10月以来，他一直担任我们的首席运营官。加入我们之前，他曾担任BioHarvest公司（创新生物科技公司）的首席运营官（2012年10月至2015年9月），此前曾担任Procognia Ltd的研发运营副总裁。此前，他曾担任Omrix Biopharmaceuticals Inc.（目前从属于the Johnson & Johnson家族公司）、InterPharm Labratories Ltd（Merck-Serono的子公司）的执行职务。他持有Tel Aviv University（位于以色列）的微生物和细胞生物学硕士学位、学士学位和博士学位。
- Ilana Belzer has served as our chief operating officer since October 2015. Prior to joining us, Dr. Belzer served as the chief operating officer of BioHarvest, an innovative biotechnology company, from October 2012 to September 2015 and prior to that as vice president of research and development and operations at Procognia Ltd. Prior to that, Dr. Belzer held executive positions in Omrix Biopharmaceuticals Inc., now part of the Johnson & Johnson family of companies, and InterPharm Laboratories Ltd., now a subsidiary of Merck-Serono. Dr. Belzer holds an M.Sc., a B.Sc. and a Ph.D. in Microbiology and Cell Biology from Tel Aviv University, Israel.
- Nadav Orr
Nadav Orr，他一直是我们负责研发的副总裁（2014年9月以来）。他拥有15年以上的研发经验，包括开发生物外科产品9年。加入我们之前，他曾担任Omrix Biopharmaceuticals Ltd（Ethicon US LLC的子公司，从属于Johnson & Johnson的家族企业）的研发副主管。任职Omrix公司期间，他曾领导国际团队，从事开发止血组合产品，也曾领导基础业务支持生产过程和产品。他持有the Weizmann Institute of Science（位于以色列）的哲学博士学位。
Nadav Orr has served as our vice president of research and development since September 2014. Dr. Orr has over 17 years of experience in research and development, including 12 years in the development of biosurgery products. Prior joining us, Dr. Orr served as the associate director of research and development at Omrix Biopharmaceuticals Ltd., a subsidiary of Ethicon US LLC, part of the Johnson & Johnson family of companies. As part of his role at Omrix, Dr. Orr led an international team in the development of hemostatic combination products and led base business support for production processes and products. Dr. Orr holds a Ph.D. from the Weizmann Institute of Science, Israel.- Nadav Orr，他一直是我们负责研发的副总裁（2014年9月以来）。他拥有15年以上的研发经验，包括开发生物外科产品9年。加入我们之前，他曾担任Omrix Biopharmaceuticals Ltd（Ethicon US LLC的子公司，从属于Johnson & Johnson的家族企业）的研发副主管。任职Omrix公司期间，他曾领导国际团队，从事开发止血组合产品，也曾领导基础业务支持生产过程和产品。他持有the Weizmann Institute of Science（位于以色列）的哲学博士学位。
- Nadav Orr has served as our vice president of research and development since September 2014. Dr. Orr has over 17 years of experience in research and development, including 12 years in the development of biosurgery products. Prior joining us, Dr. Orr served as the associate director of research and development at Omrix Biopharmaceuticals Ltd., a subsidiary of Ethicon US LLC, part of the Johnson & Johnson family of companies. As part of his role at Omrix, Dr. Orr led an international team in the development of hemostatic combination products and led base business support for production processes and products. Dr. Orr holds a Ph.D. from the Weizmann Institute of Science, Israel.
- Philippe Bensimon
Philippe Bensimon，他一直是我们的负责监管事务和质量保证的副总裁（2011年2月以来）。他拥有19年的国际医疗设备公司的监管事务、质量保证和临床事务经验。加入我们之前，他曾任职InterVascular Datascope（现称为Maquet-Getinge Group，长期心血管植入物的制造商）14年，其中包括监管事务、质量保证和临床事务董事。他也曾担任3M Medical公司的合规事务经理5年。他持有the University of Pharmacy（位于法国马赛）的制药学位。
Philippe Bensimon has served as our vice president of quality assurance and clinical affairs since February 2011. Dr. Bensimon has 26 years of experience in regulatory affairs, quality assurance and clinical affairs in international medical device companies. Prior to joining us Dr. Bensimon served for 14 years at InterVascular Datascope now Maquet-Getinge Group, a manufacturer of long-term cardiovascular implants, as director of regulatory affairs, quality assurance, and clinical affairs. Dr. Bensimon also served for five years at 3M Medical as manager of regulatory affairs. Dr. Bensimon holds a PharmD degree from the University of Pharmacy, Marseille, France.- Philippe Bensimon，他一直是我们的负责监管事务和质量保证的副总裁（2011年2月以来）。他拥有19年的国际医疗设备公司的监管事务、质量保证和临床事务经验。加入我们之前，他曾任职InterVascular Datascope（现称为Maquet-Getinge Group，长期心血管植入物的制造商）14年，其中包括监管事务、质量保证和临床事务董事。他也曾担任3M Medical公司的合规事务经理5年。他持有the University of Pharmacy（位于法国马赛）的制药学位。
- Philippe Bensimon has served as our vice president of quality assurance and clinical affairs since February 2011. Dr. Bensimon has 26 years of experience in regulatory affairs, quality assurance and clinical affairs in international medical device companies. Prior to joining us Dr. Bensimon served for 14 years at InterVascular Datascope now Maquet-Getinge Group, a manufacturer of long-term cardiovascular implants, as director of regulatory affairs, quality assurance, and clinical affairs. Dr. Bensimon also served for five years at 3M Medical as manager of regulatory affairs. Dr. Bensimon holds a PharmD degree from the University of Pharmacy, Marseille, France.